Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients: 8-year follow-up of CARE-MS II (Topaz Study)

Authors
Category Primary study
JournalMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: 530de8e0f3d4fede9655b77d2e87bac492df03c2
First added on: Feb 11, 2025